These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 3360258)

  • 101. Challenges in the management of pancreatic exocrine insufficiency.
    Shandro BM; Nagarajah R; Poullis A
    World J Gastrointest Pharmacol Ther; 2018 Oct; 9(5):39-46. PubMed ID: 30397535
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Gastroparesis.
    Camilleri M; Chedid V; Ford AC; Haruma K; Horowitz M; Jones KL; Low PA; Park SY; Parkman HP; Stanghellini V
    Nat Rev Dis Primers; 2018 Nov; 4(1):41. PubMed ID: 30385743
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency in the 21(st) century.
    Trang T; Chan J; Graham DY
    World J Gastroenterol; 2014 Sep; 20(33):11467-85. PubMed ID: 25206255
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Potential role of gabapentin and extended-release gabapentin in the management of menopausal hot flashes.
    Yadav M; Volkar J
    Int J Gen Med; 2013; 6():657-64. PubMed ID: 23950657
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Chitosan as a pore former in coated beads for colon specific drug delivery of 5-ASA.
    Omwancha WS; Mallipeddi R; Valle BL; Neau SH
    Int J Pharm; 2013 Jan; 441(1-2):343-51. PubMed ID: 23200955
    [TBL] [Abstract][Full Text] [Related]  

  • 106. In Vitro Comparison of Physical Parameters, Enzyme Activity, Acid Resistance, and pH Dissolution Characteristics of Enteric-Coated Pancreatic Enzyme Preparations: Implications for Clinical Variability and Pharmacy Substitution.
    Kuhn RJ; Eyting S; Henniges F; Potthoff A
    J Pediatr Pharmacol Ther; 2007 Apr; 12(2):115-28. PubMed ID: 23055848
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Steady-state pharmacokinetics of gabapentin after administration of a novel gastroretentive extended-release formulation in postmenopausal women with vasomotor symptoms.
    Cowles VE; Gordi T; Hou SY
    Clin Drug Investig; 2012 Sep; 32(9):593-601. PubMed ID: 22775354
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Enzyme replacement therapy for pancreatic insufficiency: present and future.
    Fieker A; Philpott J; Armand M
    Clin Exp Gastroenterol; 2011; 4():55-73. PubMed ID: 21753892
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Safety and tolerability of a new formulation of pancrelipase delayed-release capsules (CREON) in children under seven years of age with exocrine pancreatic insufficiency due to cystic fibrosis: an open-label, multicentre, single-treatment-arm study.
    Graff GR; McNamara J; Royall J; Caras S; Forssmann K
    Clin Drug Investig; 2010; 30(6):351-64. PubMed ID: 20441244
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Delayed release pancrelipase for treatment of pancreatic exocrine insufficiency associated with chronic pancreatitis.
    Krishnamurty DM; Rabiee A; Jagannath SB; Andersen DK
    Ther Clin Risk Manag; 2009 Jun; 5(3):507-20. PubMed ID: 19707261
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Treatment of pancreatic exocrine deficiency.
    Sarner M
    World J Surg; 2003 Nov; 27(11):1192-5. PubMed ID: 14534818
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Pyloric motility after pylorus-preserving gastrectomy with or without the pyloric branch of the vagus nerve.
    Nakabayashi T; Mochiki E; Garcia M; Haga N; Suzuki T; Asao T; Kuwano H
    World J Surg; 2002 May; 26(5):577-83. PubMed ID: 12098048
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Postcibal gastric emptying of pancreatin pellets: effects of dose and meal oil.
    Meyer JH; Lake R; Elashoff JD
    Dig Dis Sci; 2001 Sep; 46(9):1846-52. PubMed ID: 11575435
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Factors affecting performance in an ultraendurance triathlon.
    Laursen PB; Rhodes EC
    Sports Med; 2001; 31(3):195-209. PubMed ID: 11286356
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Control of malabsorption in cystic fibrosis.
    Littlewood JM; Wolfe SP
    Paediatr Drugs; 2000; 2(3):205-22. PubMed ID: 10937471
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Gastric emptying of indigestible versus digestible oils and solid fats in normal humans.
    Meyer JH; Elashoff JD; Lake R
    Dig Dis Sci; 1999 Jun; 44(6):1076-82. PubMed ID: 10389676
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Gastric emptying and intestinal transit of pancreatic enzyme supplements in cystic fibrosis.
    Taylor CJ; Hillel PG; Ghosal S; Frier M; Senior S; Tindale WB; Read N
    Arch Dis Child; 1999 Feb; 80(2):149-52. PubMed ID: 10325730
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Assessment of gastric emptying: comparison of solid scintigraphic emptying and emptying of radiopaque markers in patients and healthy subjects.
    Stotzer PO; Fjälling M; Grétarsdóttir J; Abrahamsson H
    Dig Dis Sci; 1999 Apr; 44(4):729-34. PubMed ID: 10219830
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Lipids infused into the jejunum accelerate small intestinal transit but delay ileocolonic transit of solids and liquids.
    Hammer J; Hammer K; Kletter K
    Gut; 1998 Jul; 43(1):111-6. PubMed ID: 9771414
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Uses and abuses of enzyme therapy in cystic fibrosis.
    Durie P; Kalnins D; Ellis L
    J R Soc Med; 1998; 91 Suppl 34(Suppl 34):2-13. PubMed ID: 9709382
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.